Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $40
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson maintains an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $35 to $40.
August 04, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst maintains an Outperform rating on Revolution Medicines and raises the price target from $35 to $40.
The raised price target by Oppenheimer indicates a positive outlook for Revolution Medicines. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100